Stroke a study of thrombolytic drug therapies
Download
1 / 4

Stroke: A Study of Thrombolytic Drug Therapies - PowerPoint PPT Presentation


  • 86 Views
  • Uploaded on

Stroke: A Study of Thrombolytic Drug Therapies. Chuck R. Pearson East Tennessee State University Research in Allied Health Spring 2006. Statistics. Stroke is the third leading cause of death in the United States, and the leading cause of serious, long-term disability.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Stroke: A Study of Thrombolytic Drug Therapies' - ivie


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Stroke a study of thrombolytic drug therapies

Stroke: A Study of Thrombolytic Drug Therapies

Chuck R. Pearson

East Tennessee State University

Research in Allied Health

Spring 2006


Statistics
Statistics

  • Stroke is the third leading cause of death in the United States, and the leading cause of serious, long-term disability.

  • On average, someone in the U.S. suffers a stroke every 45 seconds; every 3.1 minutes, someone dies of a stroke (Stroke Statistics, 2006).


Treatments
Treatments

  • Currently, there is one approved drug-therapy treatment for ischemic stroke called tissue-type plasminogen activator, or tPA.

  • There is a new ‘clot busting’ treatment on the horizon called desmodus rotundus plasminogen activator, or DSPA derived from vampire bat saliva.


Conclusion
Conclusion

  • More research still needs to be completed, but the outlook for DSPA looks very promising. This is excellent news for the public because it gives us a much better chance of surviving a traumatic ischemic stroke, and to avoid a life-long debilitation that often results.


ad